Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mephenoxalone is a centrally acting skeletal muscle relaxant and mild anxiolytic belonging to the oxazolidinone chemical class. Introduced in the early 1960s, it is used to treat muscle spasms, tension, and associated anxiety. It is often described as a "myopsychic relaxant" due to its dual effect on physical muscle tone and psychological tension. Mephenoxalone has been studied and marketed both as a monotherapy and in combination with other agents, such as acetaminophen for pain or tridihexethyl for gastrointestinal conditions like duodenal ulcers. Its metabolism involves hydroxylation and demethylation, and it is primarily excreted in the urine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mephenoxalone.